NASD · Healthcare · Biotechnology · USA
Caris Life Sciences Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Caris Life Sciences develops molecular profiling solutions and precision medicine diagnostics for oncology using sequencing technologies combined with artificial intelligence. The company serves clinical, academic, and biopharma markets through its Molecular Intelligence platform, offering tissue and blood-based profiling solutions. Its customers include healthcare providers, cancer centers, and pharmaceutical partners seeking genomic analysis to guide treatment decisions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Caris Life Sciences Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: its filings cover three fiscal years and projecting growth needs four in a row.
17 more funds hold it; the full list is part of the paid plan.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on CAI yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.
We do not publish one (as of the 2026-10-30 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover three fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.